• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

You poor bastards...

Quote

Anonymous

Guest
Got yourself that Blues Association pricing agreement, and yet, no Blues plans are wanting to be a part of it. Forget about Blues contracts without the clinical data showing your testing's significantly more useful than what Quest & LabCorp are doing...
 




Anonymous said:
Got yourself that Blues Association pricing agreement, and yet, no Blues plans are wanting to be a part of it. Forget about Blues contracts without the clinical data showing your testing's significantly more useful than what Quest & LabCorp are doing...
Click to expand...

Other than us, who's saying AQUA has clinical utility? Just curious...
 








In the 04/25/2013 edition:
US sues Novartis for False Claims Act violations, kickbacks
By A on Apr 25, 2013 07:55 am


The Justice Department announced two days ago it was suing the Swiss pharmaceutical giant Novartis for violations of the False Claims Act that began in 2005. It is alleged Novartis paid kickbacks to at least twenty pharmacies to ““convert” (i.e., switch) patients to Myfortic from competitor drugs and/or to oppose the use of a cheaper, generic immunosuppressant drug.”

Myfortic is a long-term immunosuppressant used for solid organ transplant recipients.

The government alleges Novartis attempted to hide the kickbacks by disguising them as performance rebates, discounts or bonus payments. In one case, Novartis is alleged to have paid a Los Angeles pharmacist hundreds of thousands of dollars to switch 700-1,000 patients to Myfortic.
 








Top Bottom
Back
Quote